| Pair Name | Resveratrol, Sirolimus | ||
| Phytochemical Name | Resveratrol (PubChem CID: 445154 ) | ||
| Anticancer drug Name | Sirolimus (PubChem CID: 5284616 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Resveratrol, Sirolimus | |||
| Disease Info | [ICD-11: 2F7C] | Lymphangioleiomyomatosis | Investigative | |
| Gene Regulation | Down-regulation | Expression | VEGFD | KEGG ID N.A. |
| Result | The addition of resveratrol was safe and well tolerated in patients with lymphangioleiomyomatosis receiving sirolimus and was associated with modest improvement in HRQOL. Larger controlled trials of this combination may be warranted to assess definitively the usefulness of resveratrol as an additive therapy in lymphangioleiomyomatosis. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Safety and Efficacy of Combined Resveratrol and Sirolimus in Lymphangioleiomyomatosis. Chest. 2023;163(5):1144-1155. doi:10.1016/j.chest.2023.01.007. | Click |
